Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136,335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Davis KL, et al. Among authors: liu x. Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192573 Free PMC article. Clinical Trial.
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM. Rheingold SR, et al. Among authors: liu x. Br J Haematol. 2017 May;177(3):467-474. doi: 10.1111/bjh.14569. Epub 2017 Mar 14. Br J Haematol. 2017. PMID: 28295182 Free PMC article. Clinical Trial.
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. Geller JI, et al. Among authors: liu x. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26565. doi: 10.1002/pbc.26565. Epub 2017 Apr 27. Pediatr Blood Cancer. 2017. PMID: 28449393 Free PMC article. Clinical Trial.
Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL, Liu X, Minard CG, Fox E, Weigel B, Blaney S. Leary SES, et al. Among authors: liu x. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. doi: 10.1158/1078-0432.CCR-16-2882. Epub 2017 Jul 27. Clin Cancer Res. 2017. PMID: 28751444 Free PMC article.
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ. Chuk MK, et al. Among authors: liu x. Pediatr Blood Cancer. 2018 Aug;65(8):e27077. doi: 10.1002/pbc.27077. Epub 2018 Apr 25. Pediatr Blood Cancer. 2018. PMID: 29693796 Free PMC article. Clinical Trial.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM. Schafer ES, et al. Among authors: liu x. Pediatr Blood Cancer. 2018 Aug;65(8):e27066. doi: 10.1002/pbc.27066. Epub 2018 May 2. Pediatr Blood Cancer. 2018. PMID: 29719113 Free PMC article. Clinical Trial.
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ. Geller JI, et al. Among authors: liu x. Cancer. 2018 Dec 1;124(23):4548-4555. doi: 10.1002/cncr.31725. Epub 2018 Nov 5. Cancer. 2018. PMID: 30394521 Free PMC article. Clinical Trial.
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson MD Jr, Voss S, Reid JM, Fox E, Weigel BJ, Blaney SM. Schafer ES, et al. Among authors: liu x. Pediatr Blood Cancer. 2020 Feb;67(2):e28073. doi: 10.1002/pbc.28073. Epub 2019 Nov 14. Pediatr Blood Cancer. 2020. PMID: 31724813 Free PMC article. Clinical Trial.
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ. Cole KA, et al. Among authors: liu x. Clin Cancer Res. 2020 Mar 15;26(6):1213-1219. doi: 10.1158/1078-0432.CCR-19-3470. Epub 2019 Dec 19. Clin Cancer Res. 2020. PMID: 31857431 Free PMC article. Clinical Trial.
136,335 results
You have reached the last available page of results. Please see the User Guide for more information.